Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Patent
1999-02-23
2000-03-14
LeGuyader, John L.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
435 6, 435 911, 435325, 435366, 435455, 536 231, 536 2431, 536 2433, 536 245, C12Q 168, C12N 1500, C07H 2104
Patent
active
060371420
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of Smad2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad2. Methods of using these compounds for modulation of Smad2 expression and for treatment of diseases associated with expression of Smad2 are provided.
REFERENCES:
patent: 5801154 (1998-09-01), Boracchini et al.
de Caestecker et al., Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases, Genes Dev., 1998, 12:1587-1592.
Eppert et al., MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma, Cell, 1996, 86:543-552.
Heldin et al., TGF-beta signalling from cell membrane to nucleus through SMAD proteins, Nature, 1997, 390:465-471.
Kretzschmar et al., SMADs: mediators and regulators of TGF-beta signaling, Curr. Opin. Genet. Dev., 1998, 8:103-111.
Nomura et al., Smad2 role in mesoderm formation, left-right patterning and craniofacial development, Nature, 1998, 393:786-790.
Souchelnytskyi et al., Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling, J. Biol. Chem, 1997, 272:28107-28115.
Topper et al., CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor beta transcriptional responses in endothelial cells, Proc. Natl. Acad. Sci. U. S. A., 1998, 95:9506-9511.
Uchida et al., Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers, Cancer Res., 1996, 56:5583-5585.
Waldrip et al., Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo, Cell, 1998, 92:797-808.
Wrana, TGF-beta receptors and signalling mechanisms, Miner. Electrolyte Metab., 1998, 24:120-130.
Zhao et al., Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture, Dev. Biol., 1998, 194:182-195.
Milner et al. Nature Biotechnology 15:537-541, Jun. 1997.
Crooke, S.T. Ch1, "Antisense Research & Applications" Springer, pp. 1-50, 1998.
Branch TIBS 23:45-50, Feb. 1998.
Cowsert Lex M.
Monia Brett P.
Isis Pharmaceuticals , Inc.
LeGuyader John L.
LandOfFree
Antisense inhibition of SMAD2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense inhibition of SMAD2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense inhibition of SMAD2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-168238